These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 2728081)
1. Pharmacokinetics of methotrexate in the cerebrospinal fluid after intracerebroventricular administration in patients with meningeal carcinomatosis and altered cerebrospinal fluid flow dynamics. Miller KT; Wilkinson DS Ther Drug Monit; 1989; 11(3):231-7. PubMed ID: 2728081 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Tetef ML; Margolin KA; Doroshow JH; Akman S; Leong LA; Morgan RJ; Raschko JW; Slatkin N; Somlo G; Longmate JA; Carroll MI; Newman EM Cancer Chemother Pharmacol; 2000; 46(1):19-26. PubMed ID: 10912573 [TBL] [Abstract][Full Text] [Related]
3. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. Mehta BM; Glass JP; Shapiro WR Cancer Res; 1983 Jan; 43(1):435-8. PubMed ID: 6600162 [TBL] [Abstract][Full Text] [Related]
4. Approaching an individual methotrexate regimen in leptomeningeal carcinomatosis. Huber M; Nolting M; Bauer S; Leistner S; Schmitz U; Seyfert S J Neurol Sci; 2005 Sep; 236(1-2):37-41. PubMed ID: 15961112 [TBL] [Abstract][Full Text] [Related]
5. PBPK model of methotrexate in cerebrospinal fluid ventricles using a combined microdialysis and MRI acquisition. Brandhonneur N; Noury F; Bruyère A; Saint-Jalmes H; Le Corre P Eur J Pharm Biopharm; 2016 Jul; 104():117-30. PubMed ID: 27142258 [TBL] [Abstract][Full Text] [Related]
6. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Mason WP; Yeh SD; DeAngelis LM Neurology; 1998 Feb; 50(2):438-44. PubMed ID: 9484369 [TBL] [Abstract][Full Text] [Related]
7. Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates. Salzer W; Widemann B; McCully C; Adamson PC; Balis FM Cancer Chemother Pharmacol; 2001 Sep; 48(3):235-40. PubMed ID: 11592346 [TBL] [Abstract][Full Text] [Related]
8. Active transport of methotrexate from cerebrospinal fluid in humans. Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786 [TBL] [Abstract][Full Text] [Related]
10. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced? Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463 [TBL] [Abstract][Full Text] [Related]
13. Effect of probenecid on cerebrospinal fluid methotrexate kinetics. Howell SB; Olshen RA; Rice JA Clin Pharmacol Ther; 1979 Nov; 26(5):641-6. PubMed ID: 498706 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of nimustine, cytosine arabinoside, and methotrexate in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. Morikawa N; Mori T; Kawashima H; Takeyama M; Abe T; Kobayashi H Biol Pharm Bull; 2001 Apr; 24(4):436-8. PubMed ID: 11305611 [TBL] [Abstract][Full Text] [Related]
15. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Balis FM; Blaney SM; McCully CL; Bacher JD; Murphy RF; Poplack DG Cancer Chemother Pharmacol; 2000; 45(3):259-64. PubMed ID: 10663645 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid. Morikawa N; Mori T; Abe T; Ghoda M; Takeyama M; Hori S Ann Pharmacother; 1997 Oct; 31(10):1153-6. PubMed ID: 9337440 [TBL] [Abstract][Full Text] [Related]
18. A primate model for study of methotrexate pharmacokinetics in the central nervous system. Poplack DG; Bleyer WA; Wood JH; Kostolich M; Savitch JL; Ommaya AK Cancer Res; 1977 Jul; 37(7 Pt 1):1982-5. PubMed ID: 405092 [TBL] [Abstract][Full Text] [Related]
19. Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Becker A; Vezmar S; Linnebank M; Pels H; Bode U; Schlegel U; Jaehde U Int J Clin Pharmacol Ther; 2007 Sep; 45(9):504-15. PubMed ID: 17907593 [TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Grossman SA; Trump DL; Chen DC; Thompson G; Camargo EE Am J Med; 1982 Nov; 73(5):641-7. PubMed ID: 6814249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]